Redeye provides a research update following the Q4 report published by Initiator Pharma earlier toda...
Redeye was hoping for slightly higher Q4 numbers, but quarterly variations are not unusual.
Redeye makes some revisions based on the Q4 report.
Redeye shares its initial take on Physitrack’s Q4 results, which came in above our expectations in t...
Redeye comments on MindArk’s Q4 results, which came in softer than expected across the board.
Q-linea has improved access to growth capital and recently advanced the ASTar launch in Europe and t...
Orders +41%, sales +0%, adj. EBITA +12% vs. ABGSCe High NRIs lower quality of beat, but orders indic...
Redeye updates its view on Verve Group following its Q4 2024 report, which came in stronger than exp...
Redeye is initiating coverage of Insplorion, a sensor technology company focusing on hydrogen detect...
Redeye updates its estimates and valuation following Serstech's Q4 2024 report.
For Q4, we expect the gradual volume and price improvement to continue, while variable costs could d...
Redeye updates on W5 following its Q4-results where topline was as expected while profitability was ...
STENOCARE A/S (STENOCARE or the “Company”) published on February 27th the Company’s Q4-report for 20...
Tangiamo Touch Technology (”Tangiamo” eller ”Bolaget”) publicerade den 27 februari 2025 Bolagets del...
Luxbright AB (”Luxbright” eller ”Bolaget”) har stängt böckerna för helåret 2024, ett år präglat av e...
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H2 report.
Redeye returns with an updated view of Egetis Therapeutics following the Q4 report and the recent ap...
Q4e: revenues of DKK 341m, EBIT of DKK 19m, 6% margin At least two good reasons for earnings growth ...
Redeye provides a research update following the Q4 report published by Alzinova earlier today.
Analyst Group initiates equity research coverage on Genetic Analysis AS (“Genetic Analysis” or the “...
